RudaCure Inc., which develops tratamientos for intractable diseases, fue anunciada como a final selección for the Ministry of SMEs and Startups' Startup Leap Forward Package Program on April 28th.
This programa financiamiento se espera que be utilized for investigación on commercializing the peptide drug for tratamiento del dolor currently under desarrollo, as well as for external promotion activities.
This se espera que serve as the starting point for RudaCure Inc., which is entering its fifth year since founding, to take a leap forward.
Starting with this programa, RudaCure ha completado all preparations for ensayo clínicos of the tratamiento de la enfermedad de ojo seco and ocular mucosal damage tratamiento currently under desarrollo, and will begin full-scale reagent producción for ensayo clínicos starting next month.
Additionally, a busy schedule of comercialización activities is planned, including BIO KOREA in May, the presentación of RCI002 resultados preclínicos for dolor inducido por quimioterapia tratamiento at ASCO in June, and attendance at BIO USA.
At BIO KOREA, meetings are programado with empresas showing potential as multinational partners for RCI002,
and at BIO USA, colaboración with multinational partners interested in veterinario desarrollo de fármacos también anticipado, offering a chance to witness la empresa's rapid crecimiento.
